Lynch syndrome related cancers have a distinct immune profile. They are generally “immunogenic”, meaning there might be opportunities to develop immune-interception strategies to prevent cancer.
What is cancer “interception”?
- Intervening between diagnosis and treatment
- The process of identifying and treating cells that could develop into cancer before they become invasive and spread
- Very active area for research related to vaccines!
A new study based on work in mice showed that an EZH2 inhibitor (called GSK503) given over 9 weeks in mice lowered the number of adenomas that formed. Thus, EZH2 might be able to modulate immune-related genes.
These findings suggest that stopping (or inhibiting) EZH2 may raise immune responses, which could represent a promising framework to further develop and test EZH2 inhibitors as a cancer prevention strategy for those with Lynch Syndrome.
Learn more at: https://pubmed.ncbi.nlm.nih.gov/39946195/
Reference: Bowen, et al. JCI Insight. 2024; 10(6):e177545. PMID: 39946195.